---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342328"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2026-08-10T20:03:56+00:00"
generated_at: "2026-08-10T20:05:10.935816+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Septerna Q2 2026: net loss $13.0M, cash $516.5M, SEP-479 half-life supports once-daily dosing

## Summary
- Cash, equivalents and marketable securities totaled $516.5M as of June 30, 2026; expected to fund operations into 2029.
- Q2 2026 revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex a year ago; net loss narrowed to $13.0M from $24.8M.
- SEP-479 Phase 1 observed elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 showed positive Phase 1 results; company evaluating signal-finding studies in mast cell-driven diseases; TSHR program advancing.

## SEC filing metadata
- accession: 0001193125-26-342328
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2026-08-10T20:03:56+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/0001193125-26-342328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342328
- JSON: https://secwatch.observer/filing/0001193125-26-342328.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.